DGAP-Adhoc: Biofrontera AG: Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz(R) in Poland with medac GmbH Sp. z o.o.

2020. március 13., péntek, 13:00





DGAP-Ad-hoc: Biofrontera AG / Key word(s): Miscellaneous


Biofrontera AG: Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz(R) in Poland with medac GmbH Sp. z o.o.


13-March-2020 / 13:00 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Ad-hoc Release pursuant to Art. 17 MAR

Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz(R) in Poland with medac GmbH Sp. z o.o.



Leverkusen, Germany, March 13, 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement with medac GmbH Sp. z o.o., the Polish branch of medac Gesellschaft für klinische Spezialpräparate mbH, for the marketing of Ameluz(R) and BF-RhodoLED(R) in Poland.



Ameluz(R) has a centralized European drug approval which currently includes the treatment of mild and moderate actinic keratoses, field cancerization, photodynamic therapy with daylight, as well as nodular and superficial basal cell carcinoma. Ameluz(R) is used in combination with daylight or a red-light lamp, Biofrontera"s BF-RhodoLED(R).



The term sheet contains terms and conditions regarding the amount of the one-time upfront payment of around EUR 200,0000, the term of approximately 5 years, the transfer price for Ameluz(R) and BF-RhodoLED(R), as well as local regulatory responsibilities in Poland.



medac Gesellschaft für klinische Spezialpräparate mbH is a global pharmaceutical company based in Germany, which has been specializing in the treatment and diagnosis of oncological, urological and autoimmune diseases. In Poland, the company has a leading sales structure in dermatology.



Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen

ISIN: DE0006046113

WKN: 604611



Contact: Biofrontera AG

Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290

E-mail: ir@biofrontera.com











13-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



























Language: English
Company: Biofrontera AG

Hemmelrather Weg 201

51377 Leverkusen

Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 996981





 
End of Announcement DGAP News Service




996981  13-March-2020 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=996981&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.

Közzétételek - archívum